Peritoneal dialysis (PD) is a well-established form of therapy for stage 5 chronic kidney disease requiring renal replacement therapy. D-Glucose has been used successfully for several decades as the osmotic agent employed in dialysis solutions to achieve adequate fluid removal. The absorption of 100–200 grams of glucose per day has been suggested as potentially increasing cardiometabolic risk, particularly in patients with diabetes. Supporting and undermining evidence for this hypothesis is reviewed, with a focus on the role of glucose absorption in changes in body composition, dyslipidemia, and glycemic control in diabetic PD patients. Clinical strategies to optimize fluid removal while minimizing the metabolic impact of glucose absorption are also discussed.
United States Renal Data System. USRDS Coordinating Center; 2008. Available from: http://www.usrds.org.
2.
HolmesCJ. Glucotoxicity in peritoneal dialysis—solutions for the solution!Adv Chronic Kidney Dis.2007;14 (30): 269–78.
3.
MarshallJJenningsPScottAFluckRJMcIntyreCW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int.2003;64 (4): 1480–6.
4.
HithaishiCLobbedezTPadmanabhanSPinedaMEOreopoulosDG. No beneficial effect of icodextrin on blood glucose control. Perit Dial Int.2004;24 (2): 199–200.
5.
JohnsonDWArndtMO'SheaAWattRHamiltonJVincentK. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol.2001;2: 2.
6.
PaniaguaRVenturaMDAvila-DiazMCisnerosAVicente-MartinezMFurlongMDGarcia-GonzalezZVillanuevaDOrihuelaOPrado-UribeMDAlcantaraGAmatoD. Icodextrin improves metabolic and fluid management in high and highaverage transport diabetic patients. Perit Dial Int.2009;29 (4): 422–32.
7.
BabazonoTNakamotoHKasaiKKuriyamaSSugimotoTNakayamaMHamadaCFuruyaRHasegawaHKasaharaMMoriishiMTomoTMiyazakiMSatoMYoriokaNKawaguchiY. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol.2007;27 (4): 409–15.
8.
KovesdyCPSharmaKKalantar-ZadehK. Glycemic control in diabetic CKD patients: where do we stand?. Am J Kidney Dis.2008;52 (4): 766–77.
9.
WilliamsMELacsonEJrTengMOfsthunNLazarusJM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int.2006;70 (8): 1503–9.
10.
TzamaloukasAHYuanZYMurataGHBalaskasEAvasthiPSOreopoulosDG. Clinical associations of glycemic control in diabetics on CAPD. Adv Perit Dial.1993;9: 291–4.
11.
MeerwaldtRZeebregtsCJNavisGHillebrandsJLLefrandtJDSmitAJ. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis.2009;53 (1): 138–50.
12.
PeacockTPShihabiZKBleyerAJDolbareELByersJRKnovichMACalles-EscandonJRussellGBFreedmanBI. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int.2008;73 (9): 1062–8.
13.
MeerwaldtRHartogJWGraaffRHuismanRJLinksTPden HollanderNCThorpeSRBaynesJWNavisGGansROSmitAJ. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol.2005;16 (12): 3687–93.
14.
McIntyreNMcIntyreCWJohnSChestertonLJeffresHKorsheedSOwenPBurtonJFluckR. Tissue advanced glycation end product concentration in dialysis patients. World Congress of Nephrology, Milan, Italy, 2009; p. Su416.
15.
LittleJPhillipsLRussellLGriffithsARussellGIDaviesSJ. Longitudinal lipid profiles on CAPD their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol.1998;9 (10): 1931–9.
16.
VasselaiPKamimuraMABazanelliAPPupimLBAvesaniCMda Mota RibeiroFSManfrediSRDraibeSACuppariL. Factors associated with body-fat changes in prevalent peritoneal dialysis patients. J Ren Nutr.2008;18 (4): 363–9.
17.
WangXAxelssonJNordforsLQureshiARAvesaniCBaranyPSchallingMHeimburgerOLindholmBStenvinkelP. Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. Nephrol Dial Transplant.2007;22 (1): 196–202.
18.
AbbottKCOliverDKHurstFPDasNPGaoSWPerkinsRM. Body mass index and peritoneal dialysis: “exceptions to the exception” in reverse epidemiology?. Semin Dial.2007;20 (6): 561–5.
19.
McDonaldSPCollinsJFJohnsonDW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol.2003;14 (11): 2894–901.
20.
LuQChengLTWangTWanJLiaoLLZengJQinCLiKJ. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J Ren Nutr.2008;18 (6): 495–502.
21.
YamauchiTKunoTTakadaHNaguraYKanmatsuseKTakahashiS. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. Nephrol Dial Transplant.2003;18 (9): 1842–7.
22.
HondaHQureshiARAxelssonJHeimburgerOSulimanMEBaranyPStenvinkelPLindholmB. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr.2007;86 (3): 633–8.
23.
StenvinkelPLindholmBLonnqvistFKatzarskiKHeimburgerO. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol.2000;11 (7): 1303–9.
24.
TetaDMaillardMHalabiGBurnierM. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney IntSuppl.2008: S112–8.
25.
FuruyaROdamakiMKumagaiHHishidaA. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant.2006;21 (2): 494–8.
26.
TakeguchiFNakayamaMNakaoT. Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis. Ther Apher Dial.2008;12 (3): 243–9.
VoneshEFSnyderJJFoleyRNCollinsAJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?Kidney IntSuppl.2006;S3–11.
29.
LiemYSWongJBHuninkMGde CharroFTWinkelmayerWC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int.2007;71 (2): 153–8.
30.
McDonaldSPMarshallMRJohnsonDWPolkinghorneKR. Relationship between dialysis modality and mortality. J Am Soc Nephrol.2009;20 (1): 155–63.
31.
MircescuGGarneataLFloreaLCepoiVCapsaDCovicMGherman-CaprioaraMGluhovschiGGoleaOSBarbulescuCRusESantimbreanCMardareNCovicA. The success story of peritoneal dialysis in Romania: analysis of differences in mortality by dialysis modality and influence of risk factors in a national cohort. Perit Dial Int.2006;26 (2): 266–75.
32.
ClinicalTrials.gov. IMPENDIA — PEN vs Dianeal only; improved metabolic control in diabetic CAPD and APD patients. U.S. National Institutes of Health.
